CHIP-mediated degradation of transglutaminase 2 negatively regulates tumor growth and angiogenesis in renal cancer

Oncogene

Volumn 35, Issue 28, 2016, Pages 3718-3728

  Min, B ^a   Park, H ^a   Lee, S ^a   Li, Y ^b   Choi, J M ^a   Lee, J Y ^c   Kim, J ^d   Choi, Y D ^c   Kwon, Y G ^a   Lee, H W ^a   Bae, S C ^e   Yun, C O ^b   Chung, K C ^a  

^a Yonsei University   (South Korea)

^b Hanyang University   (South Korea)

^c Yonsei University College of Medicine   (South Korea)

^d The Catholic University of Korea   (South Korea)

^e Chungbuk National University College of Medicine   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOXYL TERMINUS OF HSP70 INTERACTING PROTEIN; HEAT SHOCK PROTEIN 70; PROTEASOME; PROTEIN GLUTAMINE GAMMA GLUTAMYLTRANSFERASE 2; UBIQUITIN PROTEIN LIGASE E3; UNCLASSIFIED DRUG; GUANINE NUCLEOTIDE BINDING PROTEIN; PROTEIN BINDING; PROTEIN GLUTAMINE GAMMA GLUTAMYLTRANSFERASE; STUB1 PROTEIN, HUMAN; UBIQUITIN PROTEIN LIGASE;

AGING; ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER TISSUE; CARCINOGENESIS; CONTROLLED STUDY; DOWN REGULATION; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; KIDNEY CANCER; KIDNEY PARENCHYMA; KIDNEY TUMOR; LIFESPAN; MOUSE; NONHUMAN; POLYUBIQUITINATION; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN FUNCTION; RENAL CANCER CELL LINE; TUMOR GROWTH; UBIQUITINATION; UPREGULATION; ANIMAL; C57BL MOUSE; GENE EXPRESSION REGULATION; GENETICS; HEK293 CELL LINE; IMMUNOBLOTTING; IMMUNOHISTOCHEMISTRY; MALE; METABOLISM; NEOVASCULARIZATION (PATHOLOGY); NUDE MOUSE; PATHOLOGY; RENAL CELL CARCINOMA; TUMOR CELL LINE; VASCULARIZATION; XENOGRAFT;

ANIMALS; CARCINOMA, RENAL CELL; CELL LINE, TUMOR; GENE EXPRESSION REGULATION, NEOPLASTIC; GTP-BINDING PROTEINS; HEK293 CELLS; HUMANS; IMMUNOBLOTTING; IMMUNOHISTOCHEMISTRY; KIDNEY NEOPLASMS; MALE; MICE, INBRED C57BL; MICE, NUDE; NEOVASCULARIZATION, PATHOLOGIC; PROTEASOME ENDOPEPTIDASE COMPLEX; PROTEIN BINDING; PROTEOLYSIS; TRANSGLUTAMINASES; TRANSPLANTATION, HETEROLOGOUS; UBIQUITIN-PROTEIN LIGASES; UBIQUITINATION;

EID: 84978924294     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2015.439     Document Type: Article

References (45)

1. Erdem S, Yegen G, Telci D, Yildiz I, Tefik T, Issever H et al. The increased transglutaminase 2. expression levels during initial tumorigenesis predict increased risk of metastasis and decreased disease-free and cancer-specific survivals in renal cell carcinoma. World J Urol 2015; 33: 1553-1560.
2. Ku BM, Kim DS, Kim KH, Yoo BC, Kim SH, Gong YD et al. Transglutaminase 2 inhibition found to induce p53 mediated apoptosis in renal cell carcinoma. FASEB J 2013; 27: 3487-3495.
3. Kim DS, Choi YB, Han BG, Park SY, Jeon Y, Kim DH et al. Cancer cells promote survival through depletion of the von Hippel-Lindau tumor suppressor by protein crosslinking. Oncogene 2011; 30: 4780-4790.
4. Ku BM, Kim SJ, Kim N, Hong D, Choi YB, Lee SH et al. Transglutaminase 2 inhibitor abrogates renal cell carcinoma in xenograft models. J Cancer Res Clin Oncol 2014; 140: 757-767.
5. Greenberg CS, Birckbichler PJ, Rice RH. Transglutaminases: multifunctional crosslinking enzymes that stabilize tissues. FASEB J 1991; 5: 3071-3077.
6. Kaelin WG Jr. Molecular basis of the VHL hereditary cancer syndrome. Nat Rev Cancer 2002; 2: 673-682.
7. Pavlovich CP, Schmidt LS. Searching for the hereditary causes of renal-cell carcinoma. Nat Rev Cancer 2004; 4: 381-393.
8. Wiesener MS, Munchenhagen PM, Berger I, Morgan NV, Roigas J, Schwiertz A et al. Constitutive activation of hypoxia-inducible genes related to overexpression of hypoxia-inducible factor-1alpha in clear cell renal carcinomas. Cancer Res 2001; 61: 5215-5222.
9. Johnson TS, Fisher M, Haylor JL, Hau Z, Skill NJ, Jones R et al. Transglutaminase inhibition reduces fibrosis and preserves function in experimental chronic kidney disease. J Am Soc Nephrol 2007; 18: 3078-3088.
10. Koleganova N, Piecha G, Ritz E, Schirmacher P, Muller A, Meyer HP et al. Arterial calcification in patients with chronic kidney disease. Nephrol Dial Transplant 2009; 24: 2488-2496.
11. Chen NX, O'Neill K, Chen X, Kiattisunthorn K, Gattone VH, Moe SM. Transglutaminase 2 accelerates vascular calcification in chronic kidney disease. Am J Nephrol 2013; 37: 191-198.
12. Elsasser HP, MacDonald R, Dienst M, Kern HF. Characterization of a transglutaminase expressed in human pancreatic adenocarcinoma cells. Eur J Cell Biol 1993; 61: 321-328.
13. Verma A, Wang H, Manavathi B, Fok JY, Mann AP, Kumar R et al. Increased expression of tissue transglutaminase in pancreatic ductal adenocarcinoma and its implications in drug resistance and metastasis. Cancer Res 2006; 66: 10525-10533.
14. Mehta K, Fok J, Miller FR, Koul D, Sahin AA. Prognostic significance of tissue transglutaminase in drug resistant and metastatic breast cancer. Clin Cancer Res 2004; 10: 8068-8076.
15. Fok JY, Ekmekcioglu S, Mehta K. Implications of tissue transglutaminase expression in malignant melanoma. Mol Cancer Ther 2006; 5: 1493-1503.
16. Hwang JY, Mangala LS, Fok JY, Lin YG, Merritt WM, Spannuth WA et al. Clinical and biological significance of tissue transglutaminase in ovarian carcinoma. Cancer Res 2008; 68: 5849-5858.
17. Park D, Choi SS, Ha KS. Transglutaminase 2: a multi-functional protein in multiple subcellular compartments. Amino Acids 2010; 39: 619-631.
18. Yuan L, Siegel M, Choi K, Khosla C, Miller CR, Jackson EN et al. Transglutaminase 2 inhibitor, KCC009, disrupts fibronectin assembly in the extracellular matrix and sensitizes orthotopic glioblastomas to chemotherapy. Oncogene 2007; 26: 2563-2573.
19. Hidaka H, Seki N, Yoshino H, Yamasaki T, Yamada Y, Nohata N et al. Tumor suppressive microRNA-1285 regulates novel molecular targets: aberrant expression and functional significance in renal cell carcinoma. Oncotarget 2012; 3: 44-57.
20. Ballinger CA, Connell P, Wu Y, Hu Z, Thompson LJ, Yin LY et al. Identification of CHIP, a novel tetratricopeptide repeat-containing protein that interacts with heat shock proteins and negatively regulates chaperone functions. Mol Cell Biol 1999; 19: 4535-4545.
21. Connell P, Ballinger CA, Jiang J, Wu Y, Thompson LJ, Hohfeld J et al. The co-chaperone CHIP regulates protein triage decisions mediated by heatshock proteins. Nat Cell Biol 2001; 3: 93-96.
22. Murata S, Minami Y, Minami M, Chiba T, Tanaka K. CHIP is a chaperone-dependent E3 ligase that ubiquitylates unfolded protein. EMBO Rep 2001; 2: 1133-1138.
23. Meacham GC, Patterson C, Zhang W, Younger JM, Cyr DM. The Hsc70 co-chaperone CHIP targets immature CFTR for proteasomal degradation. Nat Cell Biol 2001; 3: 100-105.
24. Muller P, Hrstka R, Coomber D, Lane DP, Vojtesek B. Chaperone-dependent stabilization and degradation of p53 mutants. Oncogene 2008; 27: 3371-3383.
25. Bento CF, Fernandes R, Ramalho J, Marques C, Shang F, Taylor A et al. The chaperone-dependent ubiquitin ligase CHIP targets HIF-1alpha for degradation in the presence of methylglyoxal. PLoS One 2010; 5: e15062.
26. Ahmed SF, Deb S, Paul I, Chatterjee A, Mandal T, Chatterjee U et al. The chaperone-assisted E3 ligase C terminus of Hsc70-interacting protein (CHIP) targets PTEN for proteasomal degradation. J Biol Chem 2012; 287: 15996-16006.
27. Paul I, Ahmed SF, Bhowmik A, Deb S, Ghosh MK. The ubiquitin ligase CHIP regulates c-Myc stability and transcriptional activity. Oncogene 2013; 32: 1284-1295.
28. Xin H, Xu X, Li L, Ning H, Rong Y, Shang Y et al. CHIP controls the sensitivity of transforming growth factor-beta signaling by modulating the basal level of Smad3 through ubiquitin-mediated degradation. J Biol Chem 2005; 280: 20842-20850.
29. Yang M, Wang C, Zhu X, Tang S, Shi L, Cao X et al. E3 ubiquitin ligase CHIP facilitates Toll-like receptor signaling by recruiting and polyubiquitinating Src and atypical PKC{zeta}. J Exp Med 2011; 208: 2099-2112.
30. Wang S, Wu X, Zhang J, Chen Y, Xu J, Xia X et al. CHIP functions as a novel suppressor of tumour angiogenesis with prognostic significance in human gastric cancer. Gut 2013; 62: 496-508.
31. Sarkar S, Brautigan DL, Parsons SJ, Larner JM. Androgen receptor degradation by the E3 ligase CHIP modulates mitotic arrest in prostate cancer cells. Oncogene 2014; 33: 26-33.
32. Yan S, Sun X, Xiang B, Cang H, Kang X, Chen Y et al. Redox regulation of the stability of the SUMO protease SENP3 via interactions with CHIP and Hsp90. EMBO J 2010; 29: 3773-3786.
33. Xu T, Zhou Q, Zhou J, Huang Y, Yan Y, Li W et al. Carboxyl terminus of Hsp70-interacting protein (CHIP) contributes to human glioma oncogenesis. Cancer Sci 2011; 102: 959-966.
34. Jan CI, Yu CC, Hung MC, Harn HJ, Nieh S, Lee HS et al. Tid1, CHIP and ErbB2 interactions and their prognostic implications for breast cancer patients. J Pathol 2011; 225: 424-437.
35. Jang KW, Lee KH, Kim SH, Jin T, Choi EY, Jeon HJ et al. Ubiquitin ligase CHIP induces TRAF2 proteasomal degradation and NF-kappaB inactivation to regulate breast cancer cell invasion. J Cell Biochem 2011; 112: 3612-3620.
36. Min JN, Whaley RA, Sharpless NE, Lockyer P, Portbury AL, Patterson C. CHIP deficiency decreases longevity, with accelerated aging phenotypes accompanied by altered protein quality control. Mol Cell Biol 2008; 28: 4018-4025.
37. Boroughs LK, Antonyak MA, Johnson JL, Cerione RA. A unique role for heat shock protein 70 and its binding partner tissue transglutaminase in cancer cell migration. J Biol Chem 2011; 286: 37094-37107.
38. Zemskov EA, Mikhailenko I, Strickland DK, Belkin AM. Cell-surface transglutaminase undergoes internalization and lysosomal degradation: an essential role for LRP1. J Cell Sci 2007; 120: 3188-3199.
39. Filiano AJ, Bailey CD, Tucholski J, Gundemir S, Johnson GV. Transglutaminase 2 protects against ischemic insult, interacts with HIF1beta, and attenuates HIF1 signaling. FASEB J 2008; 28: 2662-2675.
40. Verma A, Guha S, Wang H, Fok JY, Koul D, Abbruzzese J et al. Tissue Transglutaminase regulates focal adhesion kinase/AKT activation by modulating PTEN expression in pancreatic cancer cells. Clin Cancer Res 2008; 14: 1997-2005.
41. Su CH, Wang CY, Lan KH, Li CP, Chao Y, Lin HC et al. Akt phosphorylation at Thr308 and Ser473 is required for CHIP-mediated ubiquitination of the kinase. Cell Signal 2011; 23: 1824-1830.
42. Yakubov B, Chelladurai B, Schmitt J, Emerson R, Turchi JJ, Matei D. Extracellular tissue transglutaminase activates noncanonical NF-κB signaling and promotes metastasis in ovarian cancer. Neoplasia 2013; 15: 609-619.
43. Wang Y, Ren F, Wang Y, Feng Y, Wang D, Jia B et al. CHIP/Stub1 functions as a tumor suppressor and represses NF-kappaB-mediated signaling in colorectal cancer. Carcinogenesis 2014; 35: 983-991.
44. Ai L, Kim WJ, Demircan B, Dyer LM, Bray KJ, Skehan RR et al. The transglutaminase 2 gene (TGM2), a potential molecular marker for chemotherapeutic drug sensitivity, is epigenetically silenced in breast cancer. Carcinogenesis 2008; 29: 510-518.
45. Dyer LM, Schooler KP, Ai L, Klop C, Qiu J, Robertson KD et al. The transglutaminase 2 gene is aberrantly hypermethylated in glioma. J Neurooncol 2011; 101: 429-440.